Caricamento...
Strategies to tackle RAS-mutated metastatic colorectal cancer
The RAS oncogene is among the most commonly mutated in cancer. RAS mutations are identified in about half of patients diagnosed with metastatic colorectal cancer (mCRC), conferring poor prognosis and lack of response to anti-epidermal growth factor receptor (EGFR) antibodies. In the last decades, se...
Salvato in:
| Pubblicato in: | ESMO Open |
|---|---|
| Autori principali: | , , , , , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Elsevier
2021
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8167159/ https://ncbi.nlm.nih.gov/pubmed/34044286 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.esmoop.2021.100156 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|